Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia最新文献

筛选
英文 中文
[Prevalence and risk factors for methicillin-resistant Staphylococcus aureus infection in children]. [儿童耐甲氧西林金黄色葡萄球菌感染的发病率和风险因素]。
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-04-01 Epub Date: 2024-01-22 DOI: 10.37201/req/113.2023
P Marín Oliván, S Ferrando Monleón, J R Bretón-Martínez, A Piolatti Luna, I Hernández Monleón, C Fuertes Latasa, D Navarro Ortega, J Colomina Rodríguez
{"title":"[Prevalence and risk factors for methicillin-resistant Staphylococcus aureus infection in children].","authors":"P Marín Oliván, S Ferrando Monleón, J R Bretón-Martínez, A Piolatti Luna, I Hernández Monleón, C Fuertes Latasa, D Navarro Ortega, J Colomina Rodríguez","doi":"10.37201/req/113.2023","DOIUrl":"10.37201/req/113.2023","url":null,"abstract":"<p><strong>Objective: </strong>The objectives of this work were to know the prevalence of methicillin-resistant S. aureus (MRSA) infections in the paediatric population of our health department, to describe the risk factors for infection by MRSA compared to those produced by methicillin-susceptible S. aureus (MSSA) and to know the antibiotic sensitivity profile of MRSA and MSSA isolates.</p><p><strong>Methods: </strong>A retrospective, descriptive and analytical study of infections produced by MRSA versus those produced by MSSA was carried out during the years 2014 to 2018. Risk factors for MRSA infection were studied using a binary logistic regression model.</p><p><strong>Results: </strong>162 patients with S. aureus infections were identified. Of these, 25 (15.4%) were MRSA. The highest percentages of MRSA infection occurred among children who required hospital admission (23.4%). In the univariate analysis the need of hospital admission, antibiotic treatment in the last 3 months, the kind of infection and past MRSA infection or colonisation reached statistical significance. However, only the need of hospital admission and antibiotic treatment in the last 3 months maintained statistical significance in the binary logistic regression model. Correct antibiotic treatment was only prescribed in 26.7% of the MRSA infection cases admitted to the hospital.</p><p><strong>Conclusions: </strong>Our results suggest the need to review empirical local treatment regimen using drugs active against MRSA in infections of probable staphylococcal origin admitted to the hospital, especially if they have received antibiotic treatment in the last 3 months.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"170-175"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10945100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139514479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Pharmacokinetic monitoring of isavuconazole in a patient with extracorporeal membrane oxygenation support]. [体外膜氧合患者中异武康唑的药代动力学监测]。
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-04-01 Epub Date: 2024-02-09 DOI: 10.37201/req/120.2023
E Herranz-Bayo, R Huarte-Lacunza, P Sánchez-Chueca, I Aguiló-Lafarga, A Pinilla-Rello, E Sampedro-Calavia
{"title":"[Pharmacokinetic monitoring of isavuconazole in a patient with extracorporeal membrane oxygenation support].","authors":"E Herranz-Bayo, R Huarte-Lacunza, P Sánchez-Chueca, I Aguiló-Lafarga, A Pinilla-Rello, E Sampedro-Calavia","doi":"10.37201/req/120.2023","DOIUrl":"10.37201/req/120.2023","url":null,"abstract":"","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"183-185"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10945098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139708930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Patient with allergy to first-line antituberculosis drugs]. [对一线抗结核药物过敏的患者]。
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-04-01 Epub Date: 2024-02-23 DOI: 10.37201/req/140.2023
X Larrea Urtaran, A Dordà Benito, L Gratacós Santanach, E Nogué Pujadas, R Aguilar Salmeron, X Salgado Serrano
{"title":"[Patient with allergy to first-line antituberculosis drugs].","authors":"X Larrea Urtaran, A Dordà Benito, L Gratacós Santanach, E Nogué Pujadas, R Aguilar Salmeron, X Salgado Serrano","doi":"10.37201/req/140.2023","DOIUrl":"10.37201/req/140.2023","url":null,"abstract":"","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"196-198"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10945104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139941406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The β Carba® test can quickly determine the carbapenemases in the microbiology laboratory]. [β Carba® 试验可在微生物实验室中快速确定碳青霉烯酶的含量]。
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-04-01 Epub Date: 2024-02-13 DOI: 10.37201/req/128.2023
J M Serrano-Romero, A Román-de-la-Torre, J M Navarro-Marí, J Gutiérrez-Fernández
{"title":"[The β Carba® test can quickly determine the carbapenemases in the microbiology laboratory].","authors":"J M Serrano-Romero, A Román-de-la-Torre, J M Navarro-Marí, J Gutiérrez-Fernández","doi":"10.37201/req/128.2023","DOIUrl":"10.37201/req/128.2023","url":null,"abstract":"","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"186-188"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10945107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139725552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cavitary pneumonia and empyema thoracis caused by multidrug resistant Nocardia otitidiscaviarum in an elderly patient. 老年多药耐药诺卡菌引起的腔性肺炎和胸脓肿1例。
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-02-01 Epub Date: 2023-11-14 DOI: 10.37201/req/042.2023
I S Pérez Ramos, M L Gurruchaga Yanes, D Fernández Vecilla, U Oiartzabal Elorriaga, M J Unzaga Barañano, J L Díaz de Tuesta Del Arco
{"title":"Cavitary pneumonia and empyema thoracis caused by multidrug resistant Nocardia otitidiscaviarum in an elderly patient.","authors":"I S Pérez Ramos, M L Gurruchaga Yanes, D Fernández Vecilla, U Oiartzabal Elorriaga, M J Unzaga Barañano, J L Díaz de Tuesta Del Arco","doi":"10.37201/req/042.2023","DOIUrl":"10.37201/req/042.2023","url":null,"abstract":"","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"97-99"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92158165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Concerning the presumptive identification of Candida kefyr on Uriselect™4 agar. 关于假丝酵母在尿检上的推定鉴定™4琼脂。
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-02-01 Epub Date: 2023-11-06 DOI: 10.37201/req/068.2023
E Gómez-Vicente, J M Navarro-Marí, E Rodríguez-Guerrero, A Rosales-Castillo, J Gutiérrez-Fernández
{"title":"Concerning the presumptive identification of Candida kefyr on Uriselect™4 agar.","authors":"E Gómez-Vicente, J M Navarro-Marí, E Rodríguez-Guerrero, A Rosales-Castillo, J Gutiérrez-Fernández","doi":"10.37201/req/068.2023","DOIUrl":"10.37201/req/068.2023","url":null,"abstract":"<p><strong>Objective: </strong>Non-albicans Candida species, such as Candida kefyr, are emerging pathogens. Chromogenic media are highly useful for the diagnosis of urinary tract infections (UTIs). The aim was to describe the behavior of this specie on a non-specific chromogenic medium.</p><p><strong>Methods: </strong>A retrospective study of cases of candiduria detected in the Microbiology laboratory of the Virgen de las Nieves Hospital in Granada (Spain) between 2016 and 2021 (N=2,130). Urine samples were quantitatively seeded on non-selective UriSelect™4 chromogenic agar.</p><p><strong>Results: </strong>Between 2016 and 2021, C. kefyr was the seventh most frequent Candida species responsible for candiduria in our setting (n=15). The macroscopic appearance of C. kefyr colonies, punctiform and bluish, allowed the direct identification of these microorganisms.</p><p><strong>Conclusions: </strong>This study provides the first description of the specific behavior of C. kefyr on UriSelect™4 agar, which differentiates it from other Candida species based on its enzymatic characteristics.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"93-96"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71490721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal. [头孢iderocol和其他新批准的抗菌药物对在西班牙和葡萄牙重症监护室康复的耐多药革兰氏阴性病原体的体外活性]。
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-02-01 Epub Date: 2023-10-26 DOI: 10.37201/req/098.2023
D Gijón, J García-Castillo, M C Fernández-López, G Bou, M Siller, J Calvo-Montes, C Pitart, J Vila, N Torno, C Gimeno, H Cruz, H Ramos, X Mulet, A Oliver, P Ruiz-Garbajosa, R Canton
{"title":"In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal.","authors":"D Gijón, J García-Castillo, M C Fernández-López, G Bou, M Siller, J Calvo-Montes, C Pitart, J Vila, N Torno, C Gimeno, H Cruz, H Ramos, X Mulet, A Oliver, P Ruiz-Garbajosa, R Canton","doi":"10.37201/req/098.2023","DOIUrl":"10.37201/req/098.2023","url":null,"abstract":"<p><strong>Objective: </strong>The antimicrobial resistance is a significant public health threat, particularly for healthcare-associated infections caused by carbapenem-resistant Gram-negative pathogens which are increasingly reported worldwide. The aim of this study was to provide data on the in vitro antimicrobial activity of cefiderocol and that of commercially available comparator antibiotics against a defined collection of recent clinical multi-drug resistant (MDR) microorganisms, including carbapenem resistant Gram-negative bacteria collected from different regions in Spain and Portugal.</p><p><strong>Methods: </strong>A total of 477 clinical isolates of Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii and Stenotrophomonas maltophilia were prospectively (n=265) and retrospectively (n=212) included (2016-2019). Susceptibility testing was performed using standard broad microdilution and results were interpreted using CLSI-2021 and EUCAST-2021 criteria.</p><p><strong>Results: </strong>Overall, cefiderocol showed a good activity against Enterobacterales isolates, being 99.5% susceptible by CLSI and 94.5% by EUCAST criteria. It also demonstrated excellent activity against P. aeruginosa and S. maltophilia isolates, all being susceptible to this compound considering CLSI breakpoints. Regarding A. baumannii (n=64), only one isolate was resistant to cefiderocol.</p><p><strong>Conclusions: </strong>Our results are in agreement with other studies performed outside Spain and Portugal highlighting its excellent activity against MDR gram-negative bacteria. Cefiderocol is a therapeutic alternative to those available for the treatment of infections caused by these MDR bacteria.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"69-77"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50164294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unresolved issues in the diagnosis of catheter related candidemia: A position paper. 导管相关念珠菌病诊断中尚未解决的问题:一份立场文件。
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-02-01 Epub Date: 2023-11-13 DOI: 10.37201/req/112.2023
A Soriano-Martín, P Muñoz, J García-Rodríguez, R Cantón, A Vena, M Bassetti, E Bouza
{"title":"Unresolved issues in the diagnosis of catheter related candidemia: A position paper.","authors":"A Soriano-Martín, P Muñoz, J García-Rodríguez, R Cantón, A Vena, M Bassetti, E Bouza","doi":"10.37201/req/112.2023","DOIUrl":"10.37201/req/112.2023","url":null,"abstract":"<p><p>The incidence and recent trends of candidemia and the contribution of the COVID-19 pandemic to its evolution are not well documented. The catheter is a major focus of Candida spp. infections, but the methods used to confirm the origin of candidemia are still based on the data generated for bacterial infection. The presence of Candida spp. on the tip of a removed catheter is the gold standard for confirmation but it is not always possible to remove it. Conservative methods, without catheter removal, have not been specifically studied for microorganisms whose times of growth are different from those of bacteria and therefore these results are not applicable to candidemia. The different Candida species do not have a particular tropism for catheter colonization and fungal biomarkers have not yet been able to contribute to the determination of the origin of candidemia. Techniques such Candida T2 Magnetic Resonance (T2MR) has not yet been applied for this purpose. Finally, there is not yet a consensus of how to proceed when Candida spp. is isolated from an extracted catheter and blood cultures obtained from simultaneous peripheral veins are negative. In this lack of firm data, a group of experts has formulated a series of questions trying to answer them based on the literature, indicating the current deficiencies and offering their own opinion. All authors agree with the conclusions of the manuscript and offer it as a position and discussion paper.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"1-16"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89721451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid AST: Possibility of inferring resistance mechanisms with complex phenotypes. 快速AST:推断具有复杂表型的抗性机制的可能性。
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-02-01 Epub Date: 2023-11-08 DOI: 10.37201/req/043.2023
J Ligero-López, I Falces-Romero, A Aranda-Díaz, D García-Ballesteros, J García-Rodríguez, E Cendejas-Bueno
{"title":"Rapid AST: Possibility of inferring resistance mechanisms with complex phenotypes.","authors":"J Ligero-López, I Falces-Romero, A Aranda-Díaz, D García-Ballesteros, J García-Rodríguez, E Cendejas-Bueno","doi":"10.37201/req/043.2023","DOIUrl":"10.37201/req/043.2023","url":null,"abstract":"<p><p>The new automated systems designed for rapid performance of AST have significantly reduced the response time for susceptibility testing of microorganisms causing bacteremia and sepsis. The Accelerate Pheno® system (AAC) is one such system. Our objective for this study was to determine whether the AAC system is capable of providing an accurate susceptibility profile to infer resistance mechanisms in different carbapenemase-producing isolates when compared to the MicroScan WalkAway System (MWS). Disk diffusion method was also performed on all isolates as a reference method. Additionally, we compared the results obtained with the routine AST production system. We selected 19 isolates from the cryobank of the Microbiology department, all of which were carbapenemase-producing gram-negative bacilli. AAC was able to identify and infer the resistance of a total of 10 isolates, with an EA and CA of 84.2% for meropenem and 88.2% and 64.7% for ertapenem EA and CA, respectively. If we consider the disk diffusion technique, the CA was 57.9% and 76.5% for meropenem and ertapenem. However, in the presence of carbapenemases, AAC was not able to provide adequate MICs or infer the resistance mechanisms of the isolates accurately. Further studies with a larger number of isolates, including the new antibiotics ceftolozane/tazobactam and ceftazidime/avibactam, are needed for a more comprehensive comparison.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"88-92"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71490722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dalbavancin as a treatment option for Rothia aeria endocarditis. 将达巴万星作为治疗水飞蓟马心内膜炎的一种选择。
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-02-01 Epub Date: 2023-12-21 DOI: 10.37201/req/051.2023
H Toledo, A Gimeno, J C Alarcón, R Luque-Márquez
{"title":"Dalbavancin as a treatment option for Rothia aeria endocarditis.","authors":"H Toledo, A Gimeno, J C Alarcón, R Luque-Márquez","doi":"10.37201/req/051.2023","DOIUrl":"10.37201/req/051.2023","url":null,"abstract":"","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"100-101"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信